BNP Therapy Observation Unit Outcomes STudy (BOOST)

• Status: Terminated
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that patients admitted to an emergency department (ED) observation unit will have a decreased rate of hospital admissions and ED recidivism when treated with nesiritide versus standard therapy. The investigators also hypothesize that decreasing B-type Natriuretic Peptide (BNP) levels during treatment in an ED observation unit will predict improved patient outcomes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Collaborator: Scios, Inc.
• Treatments: Natriuretic Peptide, Brain

Criteria

Inclusion Criteria:

• Adult patient > 18 years of age

• Have a working diagnosis of HF, as determined by the emergency physician using the Boston Criteria. A score of 8-12 is required for inclusion in the study.

• Alert, oriented and able to provide informed consent.

• Able to be contacted by telephone for follow up after discharge, and have none of the study exclusion criteria.

Exclusion Criteria:

• Dialysis Dependent Renal Failure

• Temperature > 38.5 degrees celsius

• Pneumonia (Infiltrates on Chest X-ray)

• Requiring IV vasoactive agents (Other than Nesiritide)

• Killip Class III/IV

• Systolic blood pressure < 90 mmHg

• EKG diagnostic or suggestive of Acute myocardial infarction or ischemia

• Abnormal Cardiac Markers

• Lack of a telephone

• Inability to provide informed consent due to cognitive impairment or a severe psychiatric disorder